1991
DOI: 10.1007/bf02555844
|View full text |Cite
|
Sign up to set email alerts
|

Analgesic effect of Salmon calcitonin in osteoporotic vertebral fractures: A double-blind placebo-controlled clinical study

Abstract: Back pain due to vertebral collapse is the main symptom of postmenopausal osteoporosis. The clinical picture in these crush fractures varies, depending on the type and the location of fracture, but in general, a new vertebral crush fracture gives rise to severe pain that immobilizes the patient and necessitates bedrest. In this double-blind controlled clinical trial, 56 patients who had recently (within the last 3 days) suffered an osteoporotic vertebral fracture were hospitalized for a period of 14 days. Salm… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
66
1
6

Year Published

1998
1998
2007
2007

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 162 publications
(73 citation statements)
references
References 7 publications
0
66
1
6
Order By: Relevance
“…Calcitonin, given for 1-3 months following acute vertebral crush fracture, has been shown in several RCTs to decrease morbidity, improve remobilisation and prevent immobilisation bone loss. [125][126][127] The mechanism for the decrease in bone pain induced by calcitonin is not known for certain but may involve the release of endogenous endorphins. The use of calcitonin in this manner is beyond the scope of this review, which focuses upon its long-term use, but a small effect on bone pain is included in the quality-adjusted life-year (QALY) estimate (see chapter 3).…”
Section: Calcitoninmentioning
confidence: 99%
“…Calcitonin, given for 1-3 months following acute vertebral crush fracture, has been shown in several RCTs to decrease morbidity, improve remobilisation and prevent immobilisation bone loss. [125][126][127] The mechanism for the decrease in bone pain induced by calcitonin is not known for certain but may involve the release of endogenous endorphins. The use of calcitonin in this manner is beyond the scope of this review, which focuses upon its long-term use, but a small effect on bone pain is included in the quality-adjusted life-year (QALY) estimate (see chapter 3).…”
Section: Calcitoninmentioning
confidence: 99%
“…This is an approach used in early pharmacoeconomic evaluations. 88,99 Although the relationship between BMD and fracture risk is well established in untreated cohorts, the relationship between a change in BMD and change in fracture risk is less secure. 97,100,101 Indeed, recent RCT data indicate that treatment-induced changes in BMD may underestimate anti-fracture efficacy, i.e.…”
mentioning
confidence: 99%
“…Um efeito interessante da calcitonina é sua ação analgésica, que a coloca como boa opção no tratamento do quadro doloroso agudo de fratura vertebral osteoporótica (9).…”
Section: Calcitoninaunclassified